Patents by Inventor Robert D. Fleischmann
Robert D. Fleischmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8110659Abstract: The present inventors have discovered novel receptors in the Tumor Necrosis Factor (TNF) receptor family. In particular, receptors having homology to the type 2 TNF receptor (TNF-RII) are provided. Isolated nucleic acid molecules are also provided encoding the novel receptors of the present invention. Receptor polypeptides are further provided as are vectors, host cells and recombinant methods for producing the same.Type: GrantFiled: September 18, 1996Date of Patent: February 7, 2012Assignee: Human Genome Sciences, Inc.Inventors: John M. Greene, Robert D. Fleischmann, Jian Ni
-
Patent number: 7094564Abstract: A human TNF receptor and DNA (RNA) encoding such receptor and a procedure for producing such receptor by recombinant techniques is disclosed. Also disclosed are methods for utilizing such receptor for screening for antagonists and agonists to the receptor and for ligands for the receptor. Also disclosed are methods for utilizing such agonists to inhibit the growth of tumors, to stimulate cellular differentiation, to mediate the immune response and anti-viral response, to regulate growth and provide resistance to certain infections. The use of the antagonists as a therapeutic to treat autoimmune diseases, inflammation, septic shock, to inhibit graft-host reactions, and to prevent apoptosis is also disclosed. Also disclosed are diagnostic methods for detecting mutations in the nucleic acid sequence encoding the receptor and for detecting altered levels of the soluble receptor in a sample derived from a host.Type: GrantFiled: June 6, 1995Date of Patent: August 22, 2006Assignee: Human Genome Sciences, Inc.Inventors: John Greene, Robert D. Fleischmann
-
Patent number: 7078493Abstract: The present inventors have discovered novel receptors in the Tumor Necrosis Factor (TNF) receptor family. In particular, receptors having homology to the type 2 TNF receptor (TNF-RII) are provided. Isolated nucleic acid molecules are also provided encoding the novel receptors of the present invention. Receptor polypeptides are further provided as are vectors, host cells and recombinant methods for producing the same.Type: GrantFiled: March 15, 2000Date of Patent: July 18, 2006Assignee: Human Genome Sciences, Inc.Inventors: John M. Greene, Robert D. Fleischmann, Jian Ni
-
Patent number: 6955885Abstract: A human stanniocalcin-alpha polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for the regulation of electrolyte imbalances which can lead to renal, bone and heart diseases and osteoporosis and Paget's Disease. Antagonists against such polypeptides and their use in the regulation of electrolyte imbalances which can lead to hypocalcemia and osteoporosis are also disclosed. Use of the stanniocalcin-alpha sequence as a diagnostic to detect diseases or the susceptibility to diseases related to a mutated form of stanniocalcin-alpha sequences is also disclosed.Type: GrantFiled: April 18, 2003Date of Patent: October 18, 2005Assignee: Human Genome Sciences, Inc.Inventors: Henrik S. Olsen, Robert D. Fleischmann
-
Patent number: 6846651Abstract: The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO:1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies over 1700 protein encoding fragments of the genome and identifies, by position relative to a unique Not I restriction endonuclease site, any regulatory elements which modulate the expression of the protein encoding fragments of the Haemophilus genome.Type: GrantFiled: June 3, 2002Date of Patent: January 25, 2005Assignees: Human Genome Sciences, Inc., Johns Hopkins UniversityInventors: Robert D. Fleischmann, Mark D. Adams, Owen White, Hamilton O. Smith, J. Craig Venter
-
Publication number: 20040203093Abstract: The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO:1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies over 1700 protein encoding fragments of the genome and identifies, by position relative to a unique Not I restriction endonuclease site, any regulatory elements which modulate the expression of the protein encoding fragments of the Haemophilus genome.Type: ApplicationFiled: June 3, 2002Publication date: October 14, 2004Applicants: Human Genome Sciences, Inc., Johns Hopkins UniversityInventors: Robert D. Fleischmann, Mark D. Adams, Owen White, Hamilton O. Smith, J. Craig Venter
-
Publication number: 20030181663Abstract: A human stanniocalcin-alpha polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for the regulation of electrolyte imbalances which can lead to renal, bone and heart diseases and osteoporosis and Paget's Disease. Antagonists against such polypeptides and their use in the regulation of electrolyte imbalances which can lead to hypocalcemia and osteoporosis are also disclosed. Use of the stanniocalcin-alpha sequence as a diagnostic to detect diseases or the susceptibility to diseases related to a mutated form of stanniocalcin-alpha sequences is also disclosed.Type: ApplicationFiled: April 18, 2003Publication date: September 25, 2003Applicant: Human Genome Sciences, Inc.Inventors: Henrik S. Olsen, Robert D. Fleischmann
-
Patent number: 6620619Abstract: The present invention discloses three human DNA repair proteins and DNA (RNA) encoding such proteins. The DNA repair proteins may be produced by recombinant DNA techniques. One of the human DNA repair proteins, hmlh1, has been mapped on chromosome 3. The polynucleotide sequences of DNA repair proteins may be used for diagnosis of a hereditary susceptibility to cancer.Type: GrantFiled: March 16, 1994Date of Patent: September 16, 2003Assignee: Human Genome Sciences, Inc.Inventors: William A. Haseltine, Steven Ruben, Ying-Fei Wei, Mark D. Adams, Robert D. Fleischmann, Claire M. Fraser, Craig A. Rosen, Rebecca A. Fuldner, Ewen F. Kirkness
-
Publication number: 20030166097Abstract: A human TNF receptor and DNA (RNA) encoding such receptor and a procedure for producing such receptor by recombinant techniques is disclosed. Also disclosed are methods for utilizing such receptor for screening for antagonists and agonists to the receptor and for ligands for the receptor. Also disclosed are methods for utilizing such agonists to inhibit the growth of tumors, to stimulate cellular differentiation, to mediate the immune response and anti-viral response, to regulate growth and provide resistance to certain infections. The use of the antagonists as a therapeutic to treat autoimmune diseases, inflammation, septic shock, to inhibit graft-host reactions, and to prevent apoptosis is also disclosed. Also disclosed are diagnostic methods for detecting mutations in the nucleic acid sequence encoding the receptor and for detecting altered levels of the soluble receptor in a sample derived from a host.Type: ApplicationFiled: May 28, 2002Publication date: September 4, 2003Applicant: Human Genome Sciences, Inc.Inventors: John M. Greene, Robert D. Fleischmann
-
Patent number: 6613877Abstract: A human stanniocalcin-alpha polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for the regulation of electrolyte imbalances which can lead to renal, bone and heart diseases and osteoporosis and Paget's Disease. Antagonists against such polypeptides and their use in the regulation of electrolyte imbalances which can lead to hypocalcemia and osteoporosis are also disclosed.Type: GrantFiled: July 28, 1999Date of Patent: September 2, 2003Assignee: Human Genome Sciences, Inc.Inventors: Henrick S. Olsen, Robert D. Fleischmann
-
Patent number: 6610477Abstract: The present invention discloses three human DNA repair proteins and DNA (RNA) encoding such proteins and a procedure for producing such proteins by recombinant techniques. One of the human DNA repair proteins, hMLH1, has been mapped to chromosome 3 while hMLH2 has been mapped to chromosome 2 and hMLH3 has been mapped to chromosome 7. The polynucleotide sequences of the DNA repair proteins may be used for therapeutic and diagnostic treatments of a hereditary susceptibility to cancer.Type: GrantFiled: June 6, 1995Date of Patent: August 26, 2003Assignees: Human Genome Sciences, Inc., The Johns Hopkins UniversityInventors: William A. Haseltine, Steven M. Ruben, Ying-Fei Wei, Mark D. Adams, Robert D. Fleischmann, Claire M. Fraser, Rebecca A. Fuldner, Ewen F. Kirkness, Craig A. Rosen, Bert Vogelstein, Kenneth W. Kinzler, Nicholas C. Nicolaides, Nickolas Papadopoulos
-
Publication number: 20030129701Abstract: Disclosed is an RAR&egr; polypeptide and DNA (RNA) encoding the polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques and utilizing such polypeptide for therapeutic purposes, for example, tissue regeneration and stimulation of the immune and hematopoietic system. Also disclosed are methods of identifying ligands which stimulate the RAR&egr;. Also disclosed are diagnostic methods for detecting a mutation in the RAR&egr; receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host.Type: ApplicationFiled: October 24, 2002Publication date: July 10, 2003Applicant: Human Genome Sciences, Inc.Inventors: Liang Cao, Jian Ni, Robert D. Fleischmann
-
Publication number: 20030087226Abstract: The present invention discloses three human DNA repair proteins and DNA (RNA) encoding such proteins. The DNA repair proteins may be produced by recombinant DNA techniques. One of the human DNA repair proteins, hmlh1, has been mapped on chromosome 3. The polynucleotide sequences of DNA repair proteins may be used for diagnosis of a hereditary susceptibility to cancer.Type: ApplicationFiled: March 16, 1994Publication date: May 8, 2003Inventors: WILLIAM A. HASELTINE, STEVEN RUBEN, YING-FEI WEI, MARK D. ADAMS, ROBERT D. FLEISCHMANN, CLAIRE M. FRASER, CRAIG A. ROSEN, REBECCA A. FULDNER, EWEN F. KIRKNESS
-
Patent number: 6528289Abstract: The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO:1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies over 1700 protein encoding fragments of the genome and identifies, by position relative to a unique Not I restriction endonuclease site, any regulatory elements which modulate the expression of the protein encoding fragments of the Haemophilus genome.Type: GrantFiled: August 23, 2000Date of Patent: March 4, 2003Assignees: Human Genome Sciences, Inc., Johns Hopkins UniversityInventors: Robert D. Fleischmann, Mark D. Adams, Owen White, Hamilton O. Smith, J. Craig Venter
-
Publication number: 20030027177Abstract: The present invention discloses three human DNA repair proteins and DNA (RNA) encoding such proteins and a prodeudre for producing such proteins by recombinant techniques. One of the human DNA repair proteins, hMLH1, has been mapped to chromosome 3 while hMLH2 has been mapped to chromosome 2 and hMLH3 has been mapped to chromosome 7. The polynucleotide sequences of the DNA repair proteins may be used for therapeutic and diagnostic treatments of a hereditary susceptibility to cancer.Type: ApplicationFiled: February 22, 2002Publication date: February 6, 2003Applicant: Human Genome Sciences, Inc.Inventors: William A. Haseltine, Steven M. Ruben, Ying-Fei Wei, Mark D. Adams, Robert D. Fleischmann, Claire M. Fraser, Rebecca A. Fuldner, Ewen F. Kirkness, Craig A. Rosen
-
Patent number: 6506581Abstract: The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO:1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies over 1700 protein encoding fragments of the genome and identifies, by position relative to a unique Not I restriction endonuclease site, any regulatory elements which modulate the expression of the protein encoding fragments of the Haemophilus genome.Type: GrantFiled: April 25, 2000Date of Patent: January 14, 2003Assignees: Human Genome Science, Inc., Johns Hopkins UniversityInventors: Robert D. Fleischmann, Mark D. Adams, Owen White, Hamilton O. Smith, J. Craig Venter
-
Patent number: 6482606Abstract: The present invention discloses three human DNA repair proteins and DNA (RNA) encoding such proteins. The DNA repair proteins may be produced by recombinant DNA techniques. One of the human DNA repair proteins, hmlh1, has been mapped on chromosome 3. The polynucleotide sequences of DNA repair proteins may be used for diagnosis of a hereditary susceptibility to cancer.Type: GrantFiled: January 27, 1994Date of Patent: November 19, 2002Assignee: Human Genome Sciences, Inc.Inventors: Mark D. Adams, Robert D. Fleischmann, Claire M. Fraser, Rebecca A. Fuldner, Ewen F. Kirkness, William A. Haseltine, Craig A. Rosen, Steve Ruben, Ying-Fei Wei
-
Patent number: 6468765Abstract: The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO:1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies over 1700 protein encoding fragments of the genome and identifies, by position relative to a unique Not I restriction endonuclease site, any regulatory elements which modulate the expression of the protein encoding fragments of the Haemophilus genome.Type: GrantFiled: June 7, 1995Date of Patent: October 22, 2002Assignees: Human Genome Sciences, Inc., Johns Hopkins UniversityInventors: Robert D. Fleischmann, Mark D. Adams, Owen White, Hamilton O. Smith, J. Craig Venter
-
Publication number: 20020150989Abstract: A human TNF receptor and DNA (RNA) encoding such receptor and a procedure for producing such receptor by recombinant techniques is disclosed. Also disclosed are methods for utilizing such receptor for screening for antagonists and agonists to the receptor and for ligands for the receptor. Also disclosed are methods for utilizing such agonists to inhibit the growth of tumors, to stimulate cellular differentiation, to mediate the immune response and anti-viral response, to regulate growth and provide resistance to certain infections. The use of the antagonists as a therapeutic to treat autoimmune diseases, inflammation, septic shock, to inhibit graft-host reactions, and to prevent apoptosis is also disclosed. Also disclosed are diagnostic methods for detecting mutations in the nucleic acid sequence encoding the receptor and for detecting altered levels of the soluble receptor in a sample derived from a host.Type: ApplicationFiled: June 10, 2002Publication date: October 17, 2002Applicant: Human Genome Sciences, Inc.Inventors: John M. Greene, Robert D. Fleischmann
-
Publication number: 20020102634Abstract: A human stanniocalcin-alpha polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for the treatment of electrolyte disorders which lead to renal, bone and heart diseases and osteoporosis and Paget's Disease. Antagonists against such polypeptides and their use therapeutically to treat hypocalcemia and osteoporosis are also disclosed. Use of the stanniocalcin-alpha sequence as a diagnostic to detect diseases or the susceptibility to diseases related to a mutated form of stanniocalcin-alpha seqeunces is also disclosed.Type: ApplicationFiled: July 28, 1999Publication date: August 1, 2002Inventors: HENRIK S. OLSEN, ROBERT D. FLEISCHMANN